PRIMECAP MANAGEMENT CO 13D and 13G filings for BioMarin Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-12 4:01 pm Purchase |
2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO | 18,414,374 9.780% |
833,515 (+4.74%) |
Filing |
| 2023-02-09 4:01 pm Sale |
2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO | 17,580,859 9.460% |
-223,921 (-1.26%) |
Filing |
| 2022-02-10 12:21 pm Sale |
2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO | 17,804,780 9.700% |
-400,554 (-2.20%) |
Filing |
| 2021-03-08 11:02 am Purchase |
2009-02-28 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO | 18,205,334 10.030% |
57,373 (+0.32%) |
Filing |
| 2021-01-07 09:56 am Sale |
2009-02-28 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO | 18,147,961 9.997% |
-38,750 (-0.21%) |
Filing |
| 2020-09-10 12:00 pm Purchase |
2009-02-28 | 13G | BioMarin Pharmaceutical Inc. BMRN |
PRIMECAP MANAGEMENT CO | 18,186,711 10.030% |
1,857,391 (+11.37%) |
Filing |